71 patents
Page 2 of 4
Utility
Pharmaceutical Formulation
22 Jul 21
The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray.
Brian Anthony Whittle
Filed: 1 Oct 20
Utility
Use of cannabidiol in the treatment of epilepsy
20 Jul 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC).
Geoffrey Guy, Stephen Wright, Elizabeth Thiele
Filed: 12 Jan 21
Utility
Use of cannabinoids in the treatment of multiple myeloma
20 Jul 21
The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma.
Colin Stott, Massimo Nabissi
Filed: 31 Jul 17
Utility
Use of Cannabidiolic Acid In the Treatment of Autism Spectrum Disorder and Associated Disorders
8 Jul 21
The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS).
Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO
Filed: 21 Dec 20
Utility
Use of Cannabinoids In the Treatment of Epilepsy
1 Jul 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
Filed: 11 Mar 21
Utility
Use of Cannabinoids In the Treatment of Epilepsy
17 Jun 21
The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs.
Geoffrey GUY, Volker KNAPPERTZ
Filed: 30 Nov 18
Utility
Use of Cannabinoids In the Treatment of Seizures As Associated with Lennox-gastaut Syndrome
10 Jun 21
The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with Lennox-Gastaut syndrome (LGS) who are deemed to be treatment failures on their existing medication.
Geoffrey GUY, Volker KNAPPERTZ
Filed: 15 Nov 18
Utility
Use of Cannabidiol In the Treatment of Epilepsy
20 May 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC).
Geoffrey GUY, Stephen WRIGHT, Elizabeth THIELE
Filed: 12 Jan 21
Utility
Combination of cannabinoids in the treatment of leukaemia
11 May 21
The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia.
Stephen Wright, Wai Liu, Katherine Scott, Angus Dalgleish
Filed: 16 Feb 18
Utility
Extraction of Pharmaceutically Active Components from Plant Materials
6 May 21
The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament.
BRIAN ANTHONY WHITTLE, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
Filed: 18 Jun 20
Utility
Use of the Phytocannabinoid Cannabidivarin (CBDV) In the Treatment of Epilepsy
8 Apr 21
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy.
Ben WHALLEY, Claire WILLIAMS, Gary STEPHENS, Takashi FUTAMURA
Filed: 4 Sep 20
Utility
Use of cannabinoids in the treatment of epilepsy
6 Apr 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 25 Jun 20
Utility
Use of Cannabinoids In the Treatment of Epilepsy
1 Apr 21
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).
Geoffrey GUY, Stephen Wright, Orrin Devinsky
Filed: 11 Dec 20
Utility
Use of Cannabinoids In the Treatment of a Neurodegenerative Disease or Disorder
18 Mar 21
The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder.
Benjamin Whalley, William Hind, Royston Gray, Javier Fernandez-Ruiz, Eva De Lago, Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia
Filed: 10 Jul 18
Utility
Cannabinoids In Combination with Non-cannabinoid Chemotherapeutic Agents
11 Mar 21
The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer.
Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES
Filed: 23 Nov 20
Utility
Use of Cannabinoids In the Treatment of Mental Disorders
4 Mar 21
This invention relates to the use of CBD to treat mental disorders.
Philip ROBSON, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
Filed: 10 Apr 20
Utility
Modified Release Composition Comprising a Cannabinoid
4 Mar 21
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, or pharmaceutical composition, comprising a pharmaceutical formulation based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System.
Jitinder WILKHU, Johan BENDER, Mathew COLLINS
Filed: 2 Jan 19
Utility
Pharmaceutical Composition Comprising a Cannabinoid
4 Mar 21
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System.
Jitinder WILKHU, Johan BENDER
Filed: 2 Jan 19
Utility
Oral Pharmaceutical Formulation Comprising Cannabinoids and Poloxamer
4 Mar 21
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System.
Jitinder WILKHU, Johan BENDER
Filed: 2 Jan 19
Utility
Cannabidiol Preparations and Its Uses
25 Feb 21
Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol.
Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS, James BRODLE, Katarzyna LACH-FALCONE, Alan SUTTON, Royston GRAY, Rohini Rajyalaxmi RANA
Filed: 26 Apr 19